American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Author:

Lyman Gary H.12,Carrier Marc3ORCID,Ay Cihan4,Di Nisio Marcello5,Hicks Lisa K.6,Khorana Alok A.7,Leavitt Andrew D.89,Lee Agnes Y. Y.1011,Macbeth Fergus12,Morgan Rebecca L.13,Noble Simon14,Sexton Elizabeth A.15,Stenehjem David16ORCID,Wiercioch Wojtek13ORCID,Kahale Lara A.17ORCID,Alonso-Coello Pablo18ORCID

Affiliation:

1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Department of Medicine, University of Washington School of Medicine, Seattle, WA;

3. Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada;

4. Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria;

5. Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy;

6. Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada;

7. Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, OH;

8. Department of Laboratory Medicine and

9. Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA;

10. Division of Hematology, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada;

11. Division of Medical Oncology, BC Cancer, Vancouver site, Provincial Health Services Authority, Vancouver, BC, Canada;

12. Bristol, United Kingdom;

13. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;

14. Division of Population Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom;

15. Salt Lake City, UT;

16. College of Pharmacy, University of Minnesota, Duluth, MN;

17. American University of Beirut (AUB) Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Center, American University of Beirut, Beirut, Lebanon; and

18. Cochrane Iberoamérica, Biomedical Research Institute Sant Pau–CIBERESP, Barcelona, Spain

Abstract

Background: Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations. Results: Recommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer. Conclusions: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.

Publisher

American Society of Hematology

Subject

Hematology

Cited by 520 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3